279 East Grand Avenue
South San Francisco
Tel: (650) 446-6630
Freenome is a high growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease.
To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas.
We have raised more than $1.1B from leading investors including Andreessen Horowitz, Bain Capital, GV, Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Novartis, Verily, and more.
A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.
What is Freenome? First and foremost, Freenome is a team. A cross-collaborative, mission-driven team developing next-generation blood tests for early cancer detection, so that we can find cancer when it’s most treatable.
46 articles about Freenome
Walgreens and Freenome Establish Partnership to Increase Diversity in Research for the Early Detection of Cancer
Walgreens and Freenome today announced a multi-year relationship to advance clinical studies of Freenome’s blood-based tests for the early detection of cancer. Walgreens will combine its national footprint, patient insights, compliant recruitment technology and local infrastructure to engage diverse patient populations in Freenome’s multi-cancer research program.
Freenome announced it has acquired Oncimmune Ltd, a UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT Lung blood test, autoantibody platform and research and development pipeline of 7+ cancer detection signatures.
Freenome, a privately held biotech company, announced that the Institute for Population and Precision Health at the University of Chicago has joined as a study partner for its Vallania Study.
Freenome, a privately held biotech company announced that Renown Health has joined as a partner for the Sanderson Study, Freenome's study of its multiomics platform, in combination with real-world data to detect multiple cancers.
Freenome, a privately held biotech company, announced that Pennsylvania-based Geisinger is joining as a study partner for the Sanderson Study, a study for the detection of multiple cancers that pairs multiomics with real-world data.
FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS
Freenome, a privately held biotech company, presented research on Saturday at the American Society of Hematology (ASH) Annual Meeting in New Orleans.
Freenome Adds Several Community Partners to Clinical Study for the Detection of Cancer, Expanding Reach and Representation
Freenome announced 50 hospitals and community oncology practices across the United States have joined as clinical partners for its Vallania Study.
Freenome, a privately held biotech company, announced three executives have joined the company to support its continued growth.
FREENOME AND MERCK KGAA, DARMSTADT, GERMANY TO PRESENT DATA ON COMBINATION OF MULTIOMICS PROFILING AND COMPUTATIONAL MODELING AT AACR ANNUAL MEETING
Freenome announced its co-authorship of a study with Merck KGaA, Darmstadt Germany, a leading science and technology company.
Freenome Presents Research That Highlights The Significance Of Detecting Adenomas In Any Test That Screens For Colorectal Cancer
Freenome, a privately held biotech company, will present research at the American Association for Cancer Research Annual Meeting that measures the clinical impact of detecting precancerous adenomas for tests that screen for colorectal cancer, including multi-cancer early detection tests.
4/8/2022Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week.
Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study for the refinement and further development of its multiomics platform to detect multiple cancers.
Freenome, a privately held biotech company, announced that Roche has made an investment of $290 million, bringing Freenome's total funding to more than $1.1 billion since the company was founded in 2014.
Roche’s investment is aimed at supporting the development of Freenome’s colorectal cancer detection technology.
Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection
Freenome, a privately held biotech company, announced a Series D funding of $300 million. This brings the company's total financing to over $800 million since the company was founded in 2014.
Freenome, a privately held biotech company, announced a partnership with Siemens Healthineers to collaborate in multiomics and radiomic breast cancer diagnostics to identify suitable markers for early breast cancer detection through blood to augment existing imaging technologies.
Freenome, a privately held biotech company, presented new research at the American College of Gastroenterology annual meeting that underscores their commitment to improving colorectal cancer screening.
The new CEO of Freenome has a talent for “making his own weather.” That’s a phrase he heard often growing up in Rapid City, South Dakota and, when applied to his life and career, comes down to assessing himself accurately and looking for opportunities to contribute.
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
Freenome Presents Data Demonstrating the Importance of Clinical Test Performance and Screening Adherence on Colorectal Cancer Outcomes
Freenome presents findings from the CRC-MAPS™ model at the Digestive Disease Week (DDW) 2021 Annual Meeting